Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial

被引：0
作者：
Q. P. Janssen
J. L. van Dam
B. A. Bonsing
H. Bos
K. P. Bosscha
P. P. L. O. Coene
C. H. J. van Eijck
I. H. J. T. de Hingh
T. M. Karsten
M. B. van der Kolk
G. A. Patijn
M. S. L. Liem
H. C. van Santvoort
O. J. L. Loosveld
J. de Vos-Geelen
B. M. Zonderhuis
M. Y. V. Homs
G. van Tienhoven
M. G. Besselink
J. W. Wilmink
B. Groot Koerkamp
机构：
[1] Erasmus MC University Medical Center,Department of Surgery
[2] Leiden University Medical Center,Department of Surgery
[3] Tjongerschans Hospital,Department of Medical Oncology
[4] Jeroen Bosch Hospital,Department of Surgery
[5] Maasstad Hospital,Department of Surgery
[6] Catharina Hospital,Department of Surgery
[7] Department of Surgery,Department of Surgery
[8] Onze Lieve Vrouwe Gasthuis,Department of Surgery
[9] Radboud University Medical Center,Department of Surgery, Regional Academic Cancer Center Utrecht
[10] Isala Hospital,Department of Medical Oncology
[11] Department of Surgery,Department of Internal Medicine, Division of Medical Oncology
[12] Medisch Spectrum Twente,Department of Surgery, Cancer Center Amsterdam
[13] St. Antonius Hospital and University Medical Center Utrecht,Department of Medical Oncology
[14] Amphia Hospital,Department of Radiation Oncology, Cancer Center Amsterdam
[15] GROW - School for Oncology and Developmental Biology,Department of Surgery, Cancer Center Amsterdam
[16] Maastricht UMC+,Department of Medical Oncology, Cancer Center Amsterdam
[17] Amsterdam UMC,undefined
[18] Vrije Universiteit,undefined
[19] Erasmus MC University Medical Center,undefined
[20] Amsterdam UMC,undefined
[21] University of Amsterdam,undefined
[22] Amsterdam UMC,undefined
[23] University of Amsterdam,undefined
[24] Amsterdam UMC,undefined
[25] University of Amsterdam,undefined
来源：
BMC Cancer | / 21卷
关键词：
Neoadjuvant; FOLFIRINOX; Gemcitabine; Chemoradiotherapy; Localized pancreatic cancer; Intention-to-treat; Randomized controlled trial; Overall survival; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 374 条
  • [1] Paniccia A(2015)Characteristics of 10-year survivors of pancreatic ductal adenocarcinoma JAMA Surg 150 701-710
  • [2] Hosokawa P(2013)Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial Jama. 310 1473-1481
  • [3] Henderson W(2010)Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial JAMA. 304 1073-1081
  • [4] Schulick RD(2017)Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial Lancet. 389 1011-1024
  • [5] Edil BH(2018)Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer Br J Surg 105 946-958
  • [6] McCarter MD(2020)A contemporary analysis of palliative procedures in aborted pancreatoduodenectomy: morbidity, mortality, and impact on future therapy Surgery. 168 1026-1031
  • [7] Oettle H(2012)Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy J Am Coll Surg 214 33-45
  • [8] Neuhaus P(2014)Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer Ann Surg 260 372-377
  • [9] Hochhaus A(2018)Oncological benefits of Neoadjuvant Chemoradiation with gemcitabine versus upfront surgery in patients with borderline Resectable pancreatic Cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial Ann Surg 268 215-222
  • [10] Hartmann JT(2020)Preoperative Chemoradiotherapy versus immediate surgery for Resectable and borderline Resectable pancreatic Cancer: results of the Dutch randomized phase III PREOPANC trial J Clin Oncol 38 1763-1773
12345678910